Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
09:45am, Thursday, 20'th Nov 2025
The pharmaceutical giant's post-Keytruda plans continue to take shape.
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
06:57am, Thursday, 20'th Nov 2025
Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium to the biotech's prior trading price, the bid caused its shares to surge.
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
01:05pm, Wednesday, 19'th Nov 2025
In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything
04:59pm, Tuesday, 18'th Nov 2025
In one of the most decisive strategic moves in the biotech sector this year, pharmaceutical titan Merck & Co. NYSE: MRK has committed a formidable $9.2 billion in cash to acquire Cidara Therapeutics
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
10:37am, Monday, 17'th Nov 2025
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared-but seemingly missed out on a massive premium by mere weeks.
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
08:34am, Monday, 17'th Nov 2025
Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Stock Traders Purchase High Volume of Cidara Therapeutics Call Options (NASDAQ:CDTX)
02:19am, Saturday, 15'th Nov 2025
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) was the target of some unusual options trading on Friday. Traders bought 15,470 call options on the company. This is an increase of 1,606% co
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
06:17pm, Friday, 14'th Nov 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Market Today: Data Delays, CEO Shifts, M&A and Deals
05:35pm, Friday, 14'th Nov 2025
Guru Stock PicksSteven Cohen has made the following transactions:Reduce in FLR by 57.92%Sold out in TATTAdd in GDEN by 26.14%New position in KEXValueAct Capital
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)
05:30pm, Friday, 14'th Nov 2025
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
This Biotech's Stock Price More Than Doubled on Friday. Here's Why.
04:25pm, Friday, 14'th Nov 2025
Shares of Cidara Therapeutics (CDTX) more than doubled Friday after Merck (MRK) agreed to buy the biopharmaceutical firm in an all-cash deal worth $9.2 billion to expand its reach in antiviral treatme
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
03:19pm, Friday, 14'th Nov 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher
12:02pm, Friday, 14'th Nov 2025
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Friday.
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
11:20am, Friday, 14'th Nov 2025
Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.
